Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Egenlauf (Heidelberg, Germany). Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension. 3533

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Safety of switching from different prostanoids in the treatment of idiopathic pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Safety and efficacy of home-based pulmonary rehabilitation in patients with pulmonary hypertension: Feasibility study of 12 cases Source: Virtual Congress 2020 – Comprehensive care and pulmonary rehabilitation for chronic respiratory diseases Year: 2020 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005